Matthew Roden
InvestorEntrepreneur Partner at MPM BioImpact · Board director at Aktis Oncology
About
Entrepreneur Partner and CEO of portfolio company Aktis Oncology. Previously held senior leadership roles at Bristol Myers Squibb as Senior Vice President and Head of Enterprise Strategy. Earlier served as Head of Biotechnology Equity Research at UBS Investment Bank.
Board director at Aktis Oncology
Intro paths
→
In turn, Matthew can intro founders to Aktis Oncology's investors below.
Aktis Oncology's investors · 9
Andreessen HorowitzMenlo Park · $500K – $50M checks · since 2024EcoR1 CapitalSan Francisco · since 2024Janus Henderson InvestorsLondon · since 2024MPM BioImpactBoston · $1M – $15M checks · since 2024MRL Ventures FundCambridge · $25M checks · since 2024RA CapitalBoston · since 2024RTW Investments L.P.New York · since 2024TCG CrossoverPalo Alto · since 2024Vida VenturesLos Angeles · since 2024
Co-founders at Aktis Oncology
TF
Todd FoleyCo-founder and Chairman
PB
Patrick BaeuerleCo-founder & Advisor
Colleagues at MPM BioImpact
Andrew Scharenberg
Entrepreneur Partner at MPM BioImpact
Ansbert Gadicke, M.D.
Chairman at MPM BioImpact
Ansbert K. Gadicke
Managing Partner at MPM BioImpact
Aparna Parikh
Entrepreneur Partner at MPM BioImpact
Bard Geesaman
Managing Partner at MPM Capital
Binsen Li
Principal at MPM BioImpact
Brendan Furey
Chief Compliance Officer at MPM BioImpact
Brian Shuster
Entrepreneur Partner at MPM BioImpact
Frequently asked questions
- Who is Matthew Roden?
- Entrepreneur Partner and CEO of portfolio company Aktis Oncology. Previously held senior leadership roles at Bristol Myers Squibb as Senior Vice President and Head of Enterprise Strategy. Earlier served as Head of Biotechnology Equity Research at UBS Investment Bank.
- Where does Matthew Roden work?
- Matthew Roden is Entrepreneur Partner at MPM BioImpact and Board director at Aktis Oncology.